STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients with Vertebral Compression Fractures

Last updated: March 25, 2025
Sponsor: AgNovos Healthcare, LLC
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bone Fractures

Treatment

Control Group: PMMA bone cement

Treatment Group: AGN1 LOEP SV Kit

Clinical Study ID

NCT04835428
AGN-CIP-201
STAND
  • Ages > 50
  • All Genders

Study Summary

This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subject is a male or female 50 years of age or older at the time of study treatment.

  2. Subject has one (1) or two (2) acute VCF(s). Note that subjects are eligible if theyhave an asymptomatic, healed VCF(s) at any non-target vertebral level.

  3. Each target VCF meets all of the following criteria:

  4. Due to diagnosed or presumed underlying osteoporosis

  5. T1 to L5 inclusively

  6. Target VCF-related pain ≤ 6 months at time of study treatment

  7. Each target VCF shows loss of height of the vertebral body ≤ 50% based on X-ray atbaseline.

  8. Each target VCF is acute or persistent (not healed), as demonstrated on imaging,including T2-weighted, STIR MRI, bone scan or bone scan with SPECT/CT, serialradiographs, or other serial imaging demonstrating acuity.

  9. Focal tenderness to palpation of the spinal process of each target VCF on thephysical exam correlates with imaging.

  10. Subject has failed conservative medical therapy (bed rest, observation, chiropracticcare, orthotics, opioid and non-opioid analgesics, and/or physical therapy), definedas either having a VAS back pain score of ≥ 70 mm after 24 hours to 6 weeks ofconservative care or a VAS back pain score of ≥ 50 mm after more than 6 weeks ofconservative care.

  11. Subject has an Oswestry Disability Index (ODI) score of ≥ 30% at baseline.

  12. Subject is capable of giving written informed consent to participate in the study.

  13. The subject's willingness, ability, and commitment to participate in screening,treatment, and all follow-up evaluations for the full length of the study has beendocumented

Exclusion

Exclusion Criteria:

  1. At least one of the target VCF(s) is unstable, including split or burst fracture.

  2. Subject has a bleeding disorder.

  3. Subject has an active infection of the spine or surgical site.

  4. Subject has a bloodborne infection.

  5. At least one of the target VCFs is due to underlying or suspected tumor.

  6. At least one of the target VCFs is due to high-energy trauma.

  7. At least one of the target VCFs is due to osteonecrosis.

  8. At least one of the target VCFs has a local kyphotic angle of > 30 degrees, measuredas the angle between the superior endplate and inferior endplate at the target VCF.

  9. Subject has had any prior surgical treatment at the target vertebral level oradjacent vertebral levels.

  10. The pedicle(s) in the target vertebral body appears unable to safely accommodatetranspedicular access instrumentation.

  11. Subject has neurologic symptoms, deficits, or radiculopathy related to the targetVCF(s).

  12. Subject has spinal canal compromise causing clinical manifestations of cord, neuralforamen, or nerve root compression at the level to be treated.

  13. Subject has pain, progressive weakness, or paralysis due to herniated nucleuspulposus or spinal stenosis.

  14. Subject has spondylolisthesis > Grade 1 at target vertebral body(ies).

  15. Subject requires daily opioid medication for pain not related to the target VCF(s).

  16. Subject has severe cardiopulmonary deficiencies.

  17. Subject has a Body Mass Index (BMI) > 35.

  18. Subject has a history of metabolic bone disease other than osteoporosis (e.g.,Paget's disease, renal osteodystrophy, or osteomalacia).

  19. Subject has a history of tuberculous spondylitis.

  20. Subject has a history of invasive malignancy within the last five (5) years, otherthan non-melanoma skin cancer. Subject is not excluded if they have a history ofmalignancy over 5 years ago treated with curative intent and without clinical signsor symptoms since then.

  21. Subject is on oral or parenteral immune-suppressive drugs.

  22. Subject has uncontrolled diabetes mellitus.

  23. Subject has severe renal insufficiency defined as an estimated glomerular filtrationrate (eGFR) < 30 mL/min.

  24. Subject has a diagnosed calcium metabolism disorder.

  25. Subject has known allergies to calcium-based bone void fillers.

  26. Subject is pregnant or planning to become pregnant during participation in thestudy.

  27. In the judgment of the Investigator, the subject is not a good study candidate. (e.g. substance abuse or chemical dependency, inability to adhere to follow-upschedule, progression of the fracture between screening and the procedure visit).

  28. Subject is currently enrolled in another interventional clinical study.

Study Design

Total Participants: 408
Treatment Group(s): 2
Primary Treatment: Control Group: PMMA bone cement
Phase:
Study Start date:
May 31, 2022
Estimated Completion Date:
December 31, 2027

Study Description

Four hundred and eight (408) eligible subjects at up to twenty-five (25) study sites will be randomized 1:1 for treatment using the AGN1 LOEP SV Kit (Intervention Group) or PMMA bone cement (Active Control Group).

  1. Intervention Group - receives vertebral augmentation of the target VCF(s) using the AGN1 LOEP SV Kit

  2. Active Control Group - receives vertebral augmentation of the target VCF(s) using either Stryker VertaPlex HV or Medtronic Kyphon HV-R.

Follow-up visits will be conducted at 7 days, 28 days, 3 months, 12 months and 24 months after the procedure.

Connect with a study center

  • Alabama Clinical Therapeutics

    Birmingham, Alabama 35235
    United States

    Active - Recruiting

  • Elite Pain and Spine Institute

    Mesa, Arizona 85203
    United States

    Active - Recruiting

  • Mayo Clinic

    Phoenix, Arizona 85054
    United States

    Active - Recruiting

  • GW Medical Faculty Associates

    Washington, District of Columbia 20037
    United States

    Site Not Available

  • Orlando Neurosurgery (Conquest Research)

    Orlando, Florida 32804
    United States

    Active - Recruiting

  • Cleveland Clinic Florida

    Stuart, Florida 34994
    United States

    Active - Recruiting

  • Rush University Medical Center

    Chicago, Illinois 60612
    United States

    Active - Recruiting

  • NorthShore University HealthSystem

    Evanston, Illinois 60201
    United States

    Active - Recruiting

  • Duly Health / NextStage Clinical Research

    Naperville, Illinois 60564
    United States

    Site Not Available

  • Indiana Spine Group

    Carmel, Indiana 46032
    United States

    Site Not Available

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas 66160
    United States

    Active - Recruiting

  • Abay Neuroscience Center / NextStage Clinical Research

    Wichita, Kansas 67226
    United States

    Site Not Available

  • Louisiana Spine Institute

    Shreveport, Louisiana 71101
    United States

    Active - Recruiting

  • Anne Arundel Medical Center (AAMC)

    Annapolis, Maryland 21401
    United States

    Site Not Available

  • Lahey Medical Center

    Burlington, Massachusetts 01805
    United States

    Active - Recruiting

  • Washington University St. Louis

    Saint Louis, Missouri 63130
    United States

    Site Not Available

  • Washington University St. Louis

    St Louis, Missouri 63130
    United States

    Active - Recruiting

  • Montefiore

    Bronx, New York 10467
    United States

    Active - Recruiting

  • Mt. Sinai

    New York, New York 10029
    United States

    Site Not Available

  • Pinehurst Surgical Clinic

    Pinehurst, North Carolina 28374
    United States

    Active - Recruiting

  • Neuroradiology and Pain Solutions of Oklahoma

    Oklahoma City, Oklahoma 73134
    United States

    Site Not Available

  • Neurosurgical Group / NextStage Clinical Research

    Houston, Texas 77030
    United States

    Site Not Available

  • Texas Back Institute

    Plano, Texas 75093
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.